SEVERS DISEASE TREATMENT MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Severs Disease Treatment Market, By Disease Type (Acute, Chronic), By Drug (Diclofenac, Etodolac, Indomethacin, Celecoxib, Others), By Application (Over-the-counter, Prescription), By Route of Administration (Oral, Parenteral, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

On November 3, 2023, Hisamitsu Pharmaceutical, a pharmaceutical company, launched the Salonpas Diclofenac Patch 1% in Singapore. It is the first in the Salonpas line to use diclofenac, a clinically-used ingredient that is powerful and efficacious and penetrates to alleviate pain at its core. Each patch measures 7cm by 10cm and contains 15mg of diclofenac sodium. Diclofenac is a non-steroidal anti-inflammatory drug (NSAID) used to relieve severe, persistent pain, and relieve symptoms such as inflammation, swelling, stiffness, and joint pain.
On January 3, 2023, Yaral Pharma Inc., the subsidiary company of IBSA Institut Biochimique SA, a pharmaceutical company, announced the launch of diclofenac epolamine topical system 1.3%, the authorized generic of IBSA Pharma’s Flector (diclofenac epolamine) topical system. Diclofenac epolamine topical system 1.3% is a prescription nonsteroidal anti-inflammatory (NSAID) medicated patch indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions.
In December 2022, Lupin, a pharmaceutical company, announced that it had launched, Diclofenac Sodium Topical solution in the U.S. The drug is generic version of Pennsaid of Horizon Pharma Therapeutics, a pharmaceutical company. Diclofenac Sodium Topical solution is used to relieve pain from arthritis in certain joints such as those of the knees, ankles, feet, elbows, wrists, and hands.